Multiple Sclerosis Research Repository

1. “Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS” by Johannes Lorscheider et al

-”Our pooled analysis of the currently available DMTs used after conversion to SPMS suggests that, on average, these therapies have no substantial effect on relapse-unrelated disability outcomes measured by the EDSS up to 4 years; class IV evidence that for patients with SPMS, DMT has no beneficial effect on short-term disability progression”